Supplement's IBS Treatment Claim Fails UK Review Following J&J Ltd. Complaint
Executive Summary
EnteroMed fails to provide adequate support for ad claims that its supplement gel absorbs toxins and treats gastrointestinal issues, including IBS, the UK Advertising Standards Authority says. A J&J UK subsidiary marketing competing consumer health products was among the complainants about the firm's ads.
You may also be interested in...
Health & Wellness Industry News Roundup: Week Of Aug. 1
Kratom seized again; FTC warns on Zika claims; EntereoMed passes 2 of 3 UK gut health claim checks; Bevolution adds Dr. Smoothie to lineup; physicians committee recommends prebiotics; and more news in brief.
IFF Narrows Focus To Fragrance, Health, Food
International Flavors & Fragrances agrees to sell its Pharma Solutions business to plant-based ingredients company Roquette for an enterprise value of $2.85bn to reduce debt and streamline its business to three segments, including scents.
MoCRA Implementation In US Election Year: Q&A With Attorney Wade Ackerman
Wade Ackerman, partner at Covington & Burling who served previously as senior FDA counsel to US Senate Health Education, Labor & Pensions (HELP) Committee leadership, discusses expectations for FDA activity under modernized cosmetics regulations in 2024.